🧠❤️ Predict. Prevent. Protect: AI’s Lifesaving Role in HCM
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 AI vs Sudden Cardiac Death in HCM 🫀🤖 Exciting new study published in Nature Cardiovascular Research showcases MAARS, a multimodal AI model that dramatically improves risk prediction for sudden arrhythmic death in hypertrophic cardiomyopathy patients. 📊 MAARS outperformed current guidelines with AUROC of 0.89 (internal) and 0.81 (external) 🧠 Integrated data: LGE-CMR 🧲, EHR 📋, and echo/CMR reports 💻 ⚖️ Demonstrated fairness across age and sex subgroups 🔍 Transparent predictions via Shapley values and attention heatmaps A leap toward...
info_outline
💡 Personalized, Precise, Powerful: The Rise of Cancer Vaccines 🧪
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
“Vax to the Future: Cancer Immunity Revolution 🧬💉” Cancer vaccines are no longer a promise — they’re a precision revolution. From HBV and HPV to cutting-edge mRNA-based neoantigen vaccines, we explore how tumor sequencing + AI + immune checkpoint inhibitors are reshaping oncology. 📈 Real data from trials in melanoma, ccRCC, and pancreatic cancer ⚔️ PD-1 inhibitors meet targeted T cells 🌍 A safer, scalable future for cancer care 🎧 Tune in to Got Knowledge Doc as we decode this game-changing viewpoint from JCI — “Vaccines in Cancer Treatment...
info_outline
🍬 Endothelium Under Attack: The Sweetener-Inflammation Link
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New Findings on Aspartame & Heart Health! 🍬🫀 A groundbreaking study in Cell Metabolism reveals how aspartame, a common artificial sweetener, may worsen atherosclerosis via an insulin-triggered inflammatory pathway involving the CX3CL1-CX3CR1 axis. 🧪 Key insights from mice and monkeys: – Aspartame spikes insulin via vagus nerve stimulation – Elevated insulin boosts CX3CL1 expression in endothelial cells – CX3CL1 recruits inflammatory monocytes ➡️ plaque growth & instability 🧬 Blocking CX3CR1 in monocytes stopped plaque progression entirely....
info_outline
Dr RR Baliga's Philosophical Discourses: Saint Augustine of Hippo (354–430 CE)
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Saint Augustine of Hippo (354–430 CE), a prominent theologian, philosopher, and bishop in Roman North Africa, profoundly influenced Western Christianity and philosophy. Known for works like Confessions, The City of God, and On Christian Doctrine, he developed doctrines on original sin, grace, just war, and ecclesiology. His thoughts shaped medieval theology, inspired Protestant Reformers, and continue to impact Christian teachings.
info_outline
Beats, Bytes, Brilliance 🫀💾🌟: The Rise of AI in Echocardiography
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 Just out in JAMA! 💡 PanEcho, a multitask AI model trained on over 1.2 million echo videos, can automate complete echocardiographic interpretation — from LVEF to valvular disease — with diagnostic AUCs up to 1.00 and MAE as low as 4.2%. 🌍 Validated across international cohorts, including point-of-care settings, this tool could redefine access, accuracy, and efficiency in cardiac imaging. 🫀🤖 A major leap toward AI-assisted cardiovascular diagnostics. 🔗 #AIinMedicine #Cardiology #EchoRevolution #PanEcho #DigitalHealth #JAMA #MachineLearning #CardioAI...
info_outline
🔌 Power Heist in the Tumor: Neurons Fuel Cancer Spread
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New insights from cancer neuroscience! 🧠🧬 A groundbreaking Nature study reveals that cancer cells can steal mitochondria from nearby neurons via tunneling nanotubes — supercharging their metabolism, stemness, and metastatic potential 🌪️💥 Using a clever tool called MitoTRACER, researchers traced this “mitochondrial hijack” across cancers (breast, prostate, melanoma) and showed that recipient cells were more likely to seed distant metastases — especially in the brain 🧳🧠 🧪 Targeting this nerve–tumor energy axis may open new doors to stop...
info_outline
🧠💡 Memory Matters: A Cardiologist’s Guide to Cognitive Care
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🧠💓 Cognitive decline and cardiovascular disease often go hand in hand — but they don’t have to spiral together. In our latest breakdown, we explore how cardiologists can detect, manage, and even improve cognitive impairment through smart risk factor control, lifestyle changes, and a multidisciplinary approach. From MoCA to memantine, TAVR to team-based care — it’s time to connect the mind and the heart. 📊 Evidence-based strategies 🩺 Practical tools for clinicians 💡 Insights from JACC’s state-of-the-art review 👉 Let’s build heart-smart,...
info_outline
Adjuvants & Alzheimer’s: A Shot at Prevention 💥🧬🧠
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🧠💉 Can vaccines protect the mind? New research suggests that AS01-adjuvanted vaccines like Shingrix and Arexvy may reduce the risk of dementia—possibly by stimulating immune pathways like IFN-γ and TLR4, not just by preventing infection. 📊 In a large US-based EHR study, those who received the RSV or shingles vaccine had a significantly lower 18-month dementia risk than flu-vaccinated peers. 🔬 The common thread? The AS01 adjuvant. 🛡️ Could this be a new frontier in neuroprotection? Let’s discuss. #Vaccines #Dementia #RSV #AS01 #Neuroimmunology...
info_outline
💉 Pump, 📉 Pressure, ⚡ Power: Inside the STEMI Shock Solution
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
New Insights from the DanGer Shock Trial! 🫀💡 Can early left ventricular unloading with a microaxial flow pump (mAFP) save lives in STEMI-related cardiogenic shock? This compelling substudy shows that mAFP not only boosts cardiac output and power, but also reduces pulmonary pressures—all while using less pharmacologic support. 📉💊 🧪 Native CO improved steadily over 48 hours, hinting at myocardial recovery. 📊 PAC data gives us a front-row seat to the physiology behind the survival curves. 🔬 The editorial dives deeper: timing, technique, and future questions....
info_outline
🌐 ACHIEVE-1 Decoded: Efficacy & Safety of Orforglipron in Type 2 Diabetes
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬 The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉 👨⚕️ 559 patients across 5 countries ⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg) 📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6% ✅ No severe hypoglycemia 📌 Mild GI side effects during dose titration This is a potential gamechanger for early T2DM care—simple, effective, and...
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.